Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer

publication date: Dec 5, 2019

AstraZeneca and Merck/MSD were approved to sell their jointly marketed PARP inhibitor in China as a first-line maintenance treatment for BRCA-mutated ovarian cancer. In a Phase III trial among patients who responded to platinum-based chemotherapy, 60% of Lynparza patients hit the 36-month point without disease progression or death, against 27% for women receiving placebo, a 70% improvement. Results of the Phase III SOLO-1 trial showed 15% of ovarian cancer patients have a germline (inherited) BRCA 1/2 mutation and 7% have a somatic (acquired) mutation. More details....

Stock Symbols: (NYSE: AZN) (NYSE: MRK)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital